Skip to main content

Table 1 Demographic and clinical characteristics of the different serum study groups

From: The different expression of caspase-1 in HBV-related liver disease and acts as a biomarker for acute-on-chronic liver failure

Parameters Control (n = 69) CHB (n = 101) LC (n = 62) HCC (n = 80) ACLF (n = 126) P value
Age (years) 39.3 ± 6.3 40.3 ± 7.8 47.4 ± 9.2 51.1± 10.5 45.9 ± 9.8 0.066
Gender (male/female) 37/32 58/43 34/28 51/29 82/44 0.342
Alanine aminotransferase (U/L) 24.6 ± 17.2 98.8 ± 67.7 70.8 ± 26.1 63.1 ± 62.3 81.4 ± 59.9 0.008
Aspartate aminotransferase (U/L) 35.8 ± 6.4 101.1 ± 30.2 88.7 ± 19.5 77.6 ± 23.9 111.4 ± 30.1 < 0.001
Total bilirubin (μmol/l) 14.2 ± 3.9 59.7 ± 27.4 16.5 ± 8.8 21.9 ± 10.1 336.2 ± 87.3 < 0.001
Albumin (g/L) 45.6 ± 5.3 40.7 ± 5.7 38.5 ± 7.6 39.0 ± 8.3 32.4 ± 9.9 < 0.001
HBsAg positive (n) 0 101 62 80 126
HBV DNA (log10 copies/mL) 0 7.11 ± 3.9 6.37 ± 4.5 6.01 ± 2.9 5.87 ± 2.3
Creatinine (μmol/L) 74 ± 44.7 68 ± 30.6 65 ± 19.1 67 ± 52.4 63 ± 40.8 0.007
Prothrombin time (s) 10.8 ± 1.6 12.8 ± 4.0 17.9 ± 8.3 15.4 ± 7.1 25.2 ± 10.5 < 0.001
International normalized ratio 0.98 ± 0.12 1.17 ± 0.2 1.31 ± 0.22 1.25 ± 0.31 2.17 ± 0.47 < 0.001
IL-1β(pg/ml) 5.14 ± 2.64 6.81 ± 4.06 4.37 ± 2.99 5.55 ± 5.39 1.39 ± 0.82 < 0.001
IL-18(pg/m) 9.11 ± 2.66 17.61 ± 19.04 34.21 ± 33.78 50.14 ± 41.02 303.09 ± 274.54 < 0.001
  1. Abbreviations: CHB chronic hepatitis B, LC liver cirrhosis, HCC hepatocellular carcinoma, ACLF acute-on-chronic liver failure, IL-1β interleukin-1β, IL-18 interleukin-8